Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
IGM Biosciences, Inc. IGMS
$12.64
-$0.28 (-2.21%)
На 18:02, 12 мая 2023
+168.99%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
505629497.00000000
-
week52high
28.20
-
week52low
9.74
-
Revenue
1069000
-
P/E TTM
-3
-
Beta
-0.22837700
-
EPS
-5.64000000
-
Last Dividend
0.00000000
-
Next Earnings Date
08 мая 2023 г. в 10:59
Описание компании
IGM Biosciences, Inc., a biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. The company's lead product candidate is IGM-2323, a bispecific IgM antibody that is in Phase 2 clinical trials to treat patients with relapsed/refractory B cell Non-Hodgkin's lymphoma (NHL). It is also developing IGM-8444, an IgM antibody, which is in Phase 1 clinical trials for the treatment of patients with solid cancers; and IGM-7354, an anti-PD-L1 IgM antibody for the treatment of patients with solid and hematologic malignancies; IGM-2644, a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins for the treatment of patients with multiple myeloma; and IGM-2537, a bispecific T cell engaging IgM antibody targeting CD123 and CD3 proteins for the treatment of patients with acute myeloid leukemia, myelodysplastic syndromes, and acute lymphoblastic leukemia. It has a collaboration and license agreement with Genzyme Corporation to generate, develop, manufacture, and commercialize IgM antibodies. The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010. IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Truist Securities | Buy | Buy | 23 авг 2022 г. |
| Baird | Outperform | Outperform | 01 июн 2022 г. |
| HC Wainwright & Co. | Buy | Buy | 17 мая 2022 г. |
| Baird | Outperform | Outperform | 04 апр 2022 г. |
| HC Wainwright & Co. | Buy | Buy | 31 мар 2022 г. |
| B of A Securities | Buy | 29 авг 2022 г. | |
| JP Morgan | Neutral | 17 окт 2022 г. | |
| RBC Capital | Sector Perform | Sector Perform | 04 ноя 2022 г. |
| HC Wainwright & Co. | Buy | Buy | 07 ноя 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Keyt Bruce | D | 0 | 33756 | 05 янв 2023 г. |
| Keyt Bruce | A | 91997 | 33756 | 05 янв 2023 г. |
| Lee Michael Stewart | A | 2152 | 230 | 30 дек 2022 г. |
| Redmile Group, LLC | A | 3336507 | 230 | 30 дек 2022 г. |
| Topsoe Jakob Haldor | A | 74152 | 230 | 30 дек 2022 г. |
| BEHRENS M KATHLEEN | A | 3768 | 374 | 30 дек 2022 г. |
| LOBERG MICHAEL D | A | 533 | 533 | 30 дек 2022 г. |
| Topsoe Christina Teng | A | 37967 | 346 | 30 дек 2022 г. |
| Tahir Misbah | D | 27090 | 3801 | 19 дек 2022 г. |
| Takimoto Chris H | D | 30557 | 1938 | 16 дек 2022 г. |
Новостная лента
IGM Biosciences to Present at the Guggenheim 2023 Oncology Conference
GlobeNewsWire
02 февр 2023 г. в 07:00
MOUNTAIN VIEW, Calif., Feb. 02, 2023 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced that Fred Schwarzer, Chief Executive Officer, will participate in a fireside chat at the Guggenheim 2023 Oncology Conference on Thursday, February 9, 2023, at 1:35 p.m. EST in New York.
IGM Biosciences to Present at the 41st Annual J.P. Morgan Healthcare Conference
GlobeNewsWire
03 янв 2023 г. в 07:00
MOUNTAIN VIEW, Calif., Jan. 03, 2023 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing IgM antibodies, today announced that Fred Schwarzer, Chief Executive Officer, will present at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023, at 5:15 p.m. PST in San Francisco.
IGM Biosciences to Present at the Bank of America Biotech SMID Cap Conference
GlobeNewsWire
01 дек 2022 г. в 07:00
MOUNTAIN VIEW, Calif., Dec. 01, 2022 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing IgM antibodies, today announced that Fred Schwarzer, Chief Executive Officer, will participate in a virtual fireside chat at the Bank of America Biotech SMID Cap Conference on Thursday, December 8, 2022 at 2:45 p.m. EST.
IGM Biosciences to Present at Three Upcoming Investor Conferences
GlobeNewsWire
08 ноя 2022 г. в 07:00
MOUNTAIN VIEW, Calif., Nov. 08, 2022 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing IgM antibodies, today announced that Fred Schwarzer, Chief Executive Officer, will participate in fireside chats at three upcoming investor conferences:
IGM Biosciences, Inc. (IGMS) Reports Q3 Loss, Lags Revenue Estimates
Zacks Investment Research
03 ноя 2022 г. в 12:02
IGM Biosciences, Inc. (IGMS) delivered earnings and revenue surprises of 8.97% and 15.13%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?